Prokineticin-2 is associated with metabolic syndrome in a middle-aged and elderly Chinese population

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Wang, Yong ^a   Guo, Xiaoyan ^b   Ma, Heng ^c   Lu, Lin ^a   Zhang, Ruiyan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Diabetes mellitus; Lipid disorders; Metabolic syndrome; Obesity; Prokineticin 2

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROKINETICIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; GASTROINTESTINAL HORMONE; NEUROPEPTIDE; PROK2 PROTEIN, HUMAN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHINA; CHINESE; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARDIOVASCULAR DISEASE; RISK FACTOR; SAMPLE SIZE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHINA; FEMALE; GASTROINTESTINAL HORMONES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUROPEPTIDES; RISK FACTORS; ROC CURVE; SAMPLE SIZE;

EID: 84959484145     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0172-5     Document Type: Article

References (21)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-32.
3. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol (Paris). 2006;54:375-86.
4. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-54.
5. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5:70-5.
6. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141-50.
7. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol. 2001;280:E745-51.
8. Jung UJ, Choi MS. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-223.
9. Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY. Identification of two prokineticin cDNAs: Recombinant proteins potently contract gastrointestinal smooth muscle. Mol Pharmacol. 2001;59:692-8.
10. Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, Suenaga M, et al. Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem Biophys Res Commun. 2002;293:396-402.
11. Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri L, et al. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol. 2006;147:225-34.
12. Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, Screpanti I, et al. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci USA. 2009;106:14646-51.
13. Franchi S, Giannini E, Lattuada D, Lattanzi R, Tian H, Melchiorri P, et al. The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol. 2008;9:60.
14. López-Jaramillo P, Gómez-Arbelaéz D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18:37-45.
15. Golbidi S, Laher I. Exercise induced adipokine changes and the metabolic syndrome. J Diabetes Res. 2014;2014:726861.
16. Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013;2013:393192.
17. Beale K, Gardiner JV, Bewick GA, Hostomska K, Patel NA, Hussain SS, et al. Peripheral administration of prokineticin 2 potently reduces food intake and body weight in mice via the brainstem. Br J Pharmacol. 2013;168:403-10.
18. Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML, Novo S, et al. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics. J Funct Foods. 2014;6:11-32.
19. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-52.
20. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, et al. What are the risk factors and settings for nonalcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007;22:794-800.
21. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007;6:572-8.